In contrast, clinical studies with EGFR blocking drugs in advanced ovarian cancers have shown only limited efficacy [2] but in the majority of these trials, EGFR positivity was not analyzed as a selection criterion. This evidence concerns the gene EGFR and ovarian cancer.